Effector Therapeutics Ownership

Roughly 73.39 percent of Effector Therapeutics outstanding shares are held by general public with 2.9 (percent) owned by insiders and only 23.71 % by other corporate entities.
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
  
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

Effector Stock Ownership Analysis

About 24.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 12.57. Effector Therapeutics had not issued any dividends in recent years. The entity had 1:25 split on the 12th of January 2024. eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. It has a collaboration agreement with Pfizer Inc. to develop inhibitors of eIF4E. eFFECTOR Therapeutics, Inc. was founded in 2012 and is headquartered in Solana Beach, California. Effector Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 12 people. To learn more about Effector Therapeutics call Stephen Worland at 858 925 8215 or check out https://effector.com.

Effector Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Effector Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Effector Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Effector Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Presidio Management Group X Llc over six months ago
Disposition of 57580 shares by Presidio Management Group X Llc of Effector Therapeutics at 0.804 subject to Rule 16b-3
 
Warner Douglas J over six months ago
Acquisition by Warner Douglas J of 250000 shares of Effector Therapeutics subject to Rule 16b-3
 
Bhatt Elizabeth over six months ago
Acquisition by Bhatt Elizabeth of 800 shares of Effector Therapeutics at 1.38 subject to Rule 16b-3
 
Stephen Worland over six months ago
Acquisition by Stephen Worland of 1806 shares of Effector Therapeutics at 1.683 subject to Rule 16b-3
 
Presidio Management Group X Llc over six months ago
Disposition of 9726 shares by Presidio Management Group X Llc of Effector Therapeutics at 1.001 subject to Rule 16b-3
 
Warner Douglas J over a year ago
Acquisition by Warner Douglas J of 25000 shares of Effector Therapeutics subject to Rule 16b-3
 
Stephen Worland over a year ago
Acquisition by Stephen Worland of 80000 shares of Effector Therapeutics at 11.32 subject to Rule 16b-3
 
Sr One Capital Management Llc over a year ago
Sale by Sr One Capital Management Llc of 430578 shares of Effector Therapeutics
 
Stephen Worland over a year ago
Acquisition by Stephen Worland of 5979 shares of Effector Therapeutics subject to Rule 16b-3
 
Smither John W over a year ago
Acquisition by Smither John W of 20000 shares of Effector Therapeutics subject to Rule 16b-3
 
Smither John W over a year ago
Acquisition by Smither John W of 36875 shares of Effector Therapeutics subject to Rule 16b-3
 
Stephen Worland over a year ago
Acquisition by Stephen Worland of 6401 shares of Effector Therapeutics subject to Rule 16b-3

Effector Therapeutics Outstanding Bonds

Effector Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Effector Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Effector bonds can be classified according to their maturity, which is the date when Effector Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Pair Trading with Effector Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Effector Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Effector Therapeutics will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to Iron Mountain could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Iron Mountain when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Iron Mountain - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Iron Mountain Incorporated to buy it.
The correlation of Iron Mountain is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Iron Mountain moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Iron Mountain moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Iron Mountain can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.

Other Consideration for investing in Effector Stock

If you are still planning to invest in Effector Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Effector Therapeutics' history and understand the potential risks before investing.
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Stocks Directory
Find actively traded stocks across global markets
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios